ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

FDA: Safety Of Proposed Gilead HIV Drug "Generally Acceptable"

By Jennifer Corbett Dooren Of DOW JONES NEWSWIRES WASHINGTON -(Dow Jones)- The Food and Drug Administration said the safety of an experimental Gilead Sciences Inc. (GILD) HIV medicine that combines four medicines into one pill was "generally acceptable." The drug, known as the Quad, combines Gilead's double-drug Truvada, the drug elvitegravir and an agent that boosts blood levels of certain HIV drugs, cobicistat. The company is seeking FDA approval for the medicine, and the product will be reviewed Friday by the agency's antiviral drugs advisory panel. The panel of non-FDA medical experts will make a recommendation to the agency about whether it thinks the Quad should be approved. The FDA released background material Wednesday in preparation for the meeting. The agency said clinical studies of the Quad showed it met study goals looking at effectiveness by reducing viral load in patients and said adverse-events were similar among patients treated with the Quad compared to those being treated with other HIV drugs. However, the FDA said it appeared that more patients in the Quad study groups stopped the drug because of kidney-related side-effects compared to patients not receiving the drug. Gilead is hoping that the one-pill, once-daily Quad regimen will provide more convenience to HIV patients, many of whom now take multiple pills for treatment. Some analysts think it could become a blockbuster seller. Gilead submitted two clinical studies involving Quad. One 700-patient study compared it with Atripla, which combines three HIV medicines in a single, once-daily pill, as an initial therapy for HIV infection. Atripla is a combination of Gilead's Truvada with Bristol-Myers Squibb Co.'s (BMY) Sustiva. The study met its goal of showing both drugs were similar at treating HIV by suppressing the so-called viral load. The study found that 88% of Quad recipients had viral suppression 48 weeks after starting treatment, versus 84% of Atripla users. Another study involving about 700 patients compared the Quad to patients taking Truvada in addition to another HIV drug, atazanavir/ritonavir and showed the Quad reduced viral load in 90% of patients after 48 weeks compared to 87% of patients being treated with the other drugs. -By Jennifer Corbett Dooren; Dow Jones Newswires, 202-862-9294; jennifer.corbett@dowjones.com

Stock News for Gilead Sciences (GILD)
DateTimeHeadline
01/30/201518:58:13MARKET SNAPSHOT: Gasoline 'tax Cut' In Focus On Energy, Consumer-based...
01/30/201516:32:24AbbVie Hepatitis C Drug Predictions Disappoint -- Update
01/15/201500:11:45India Rejects Gilead Patent Bid
01/15/201500:05:25India Rejects Gilead Patent Bid for Sovaldi Hepatitis C Treatment...
01/08/201517:22:44AbbVie Predicts Sharp Increase in Earnings
01/04/201519:30:08Drug Prices to Get More Expensive -- Corporate Outlook
12/29/201420:26:24MARKET SNAPSHOT: S&P 500 Rises To Record, But Dow Snaps 7-day...
12/29/201420:23:11MARKET SNAPSHOT: S&P 500, Dow On Pace For Record Closes
12/29/201419:35:44MARKET SNAPSHOT: S&P 500 Hits Another Record As Stocks Edge Up
12/24/201412:21:07MARKET SNAPSHOT: U.S. Stocks Inch Higher As Santa Rally Stays...
12/24/201411:03:29MARKET SNAPSHOT: U.S. Stocks Inch Higher As Santa Stays Jolly
12/24/201411:02:54MARKET SNAPSHOT: U.S. Stocks Inch Higher; Oil Drops
12/22/201417:36:19U.S. Hot Stocks: Hot Stocks to Watch
12/11/201407:47:33GlaxoSmithKline Seeks Variation on Authorization for Ambrisentan
12/10/201416:11:30Philadelphia Agency Sues Gilead Over Price Of Hepatitis Drug--Update
12/10/201414:16:17Philadelphia Transit Agency Sues Gilead, Claiming Sovaldi Price-Gouging
10/29/201415:01:09Gilead: Buy the Dip -- Barron's
10/28/201406:48:25Biotech Bull Intact But Showing Signs of Age -- Barron's
10/27/201416:09:31Biotech Bull Intact But Showing Signs of Age
10/26/201405:18:37MARKET SNAPSHOT: Energy, Health Care Earnings To Dominate Week

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad